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Abstract
This discussion paper will explore the impact of using Magnetic Resonance Imaging (MRI) in the treat-
ment of cervical cancer with brachytherapy. It is written from the perspective of current departmental
practice in the UK and aims to highlight the issues associated with using MRI as a tool for image guided
brachytherapy planning. To support the discussion, a literature review was undertaken focussing spe-
cifically on the use of MRI in brachytherapy treatment planning for cervical cancer. Results from planning
case studies and clinical series were analysed, and the literature showed that image guided brachytherapy
treatment planning is a promising development. MRI assisted planning could theoretically be imple-
mented in centres that have access to a MRI scanner. Alternative brachytherapy technologies (e.g.
Computed Tomography (CT) assisted planning), and alternative radiotherapy modalities (e.g. an external
beam radiotherapy boost), were not found to be superior in effect or of implementation. Although MRI
shows great promise, the evidence base for MRI in brachytherapy planning for cervical cancer is currently
limited and therefore careful implementation and evaluation is required. It is suggested by the authors
that new methods of working are devised to ensure consistency and quality in implementation and
delivery, and that outcomes are measured and audited to evaluate efficacy.
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INTRODUCTION
Brachytherapy has historically played an import-
ant part in the treatment of cervical cancer. In
the 1940’s, brachytherapy was undertaken via
the manual insertion of live sources such as
radium, and dosimetric techniques—such as
the Manchester System were developed in
tandem. The Manchester System was then
adapted for use with Low Dose Rate (LDR)
afterloading machines and is still widely used.13
In the UK, 63% of centres currently use LDR
machines, and 73% of centres currently plan
treatments with orthogonal x-rays.4 The
Manchester System is still widely used, with
dose prescribed to points based upon applicator
geometry rather than tumour topography or
Organs At Risk (OAR). However, the vast
majority (83%) of these UK centres anticipate
using image guided planning for brachytherapy
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within the next three years.4 Furthermore,
LDR machines that have been popular in
the UK are now coming to the end of their
natural lives and are being phased out of
production by their manufacturers.1,3 Replace-
ment technology such as High Dose Rate
(HDR) and Pulsed Dose Rate (PDR) afterload-
ing machines offer versatility to shape dose
distributions, unlike LDR machines.5 There-
fore, there is a current opportunity for cancer
centres in the UK to re-evaluate and reassess,
as to how the different technological solutions
available will influence future management of
disease, and consider their impact upon the
service.
This discussion paper will explore the impact
of MRI on brachytherapy technology with
specific reference to the management and
treatment of cervical cancer. The role of
radiotherapy in treating cervical cancer will
be discussed, contextualising the use of
brachytherapy, and the authors will elaborate
on how this may influence the further
development of brachytherapy technology and
services.
Cervical cancer: A general overview and
use of brachytherapy in disease
management
Gynaecological cancers account for 19% of
worldwide cancer, within which cancer of the
cervix is the second most common.6 Radio-
therapy is an important part of the radical
management of cancer of the cervix; chemora-
diotherapy is the gold standard for patients
with locally advanced disease or poor pro-
gnostic indicators.7,8 Brachytherapy has tradi-
tionally been a common constituent of the
radiotherapy treatment, providing a local boost
to compliment the external beam (EBR) treat-
ment to the whole pelvis. Doses over 50 Gy
to the whole pelvis with EBR have been asso-
ciated with increased complications and lower
survival in cervical cancer,9 and hence, in com-
bination, brachytherapy allows higher doses to
be given to the primary site. However, there
are still associated risks of small bowel, rectal
and bladder toxicity.10
Using MRI for delivering brachytherapy
to cervical tumours
Image quality and target delineation
MRI has been used in staging investigations for
cervical cancer to assess the volume of disease
and the parametrial, bladder, or rectal invasion.
Lymph node status in the obturator, internal
and external iliac groups may also be assessed
with MRI, and although PET imaging is more
sensitive11 it is not widely available. In EBR,
MRI has demonstrated superior Gross Tumour
Volume (GTV) and OAR definition when
compared to portal films and CT images.12,13
Furthermore, in a large study of patients under-
going brachytherapy after EBR, MRI showed
that the visualisation of macroscopic and
partially microscopic disease, as well as areas of
tumour regression, was possible.14
Traditionally, brachytherapy planning has
relied on using orthogonal x-rays to calculate
point doses, such as to point A (Figure 1) and
the International Commission on Radiation
Units and Measurements (ICRU) bladder and
Figure 1. The position of Point A, situated 2 cm superior of the
vaginal ovoids and 2 cm lateral of the intrauterine sources.
(Reproduced by kind permission of Elsevier from Meredith WJ
(1967) ‘Radium Dosage: The Manchester System’ Second
Edition. Edinburgh, E&S Livingstone Ltd, p. 48.)
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rectal points. The use of MRI images for
patient-specific planning would allow a trans-
ition away from point doses to a volume-based
analysis and reporting. The GEC-ESTRO
recommendations15,16 suggest that areas identi-
fiable on MRI as macroscopic disease, partially
microscopic disease and tumour regression
should be used to delineate target volumes at
high or intermediate risk of local recurrence.
These Intermediate-risk Clinical Target
Volumes (IR-CTVs) or High-risk Clinical
Target Volumes (HR-CTVs) can then be used
to optimise plans to patient-specific disease
characteristics.
Image registration and applicator reconstruction
Although no extra margins are needed for
patient related uncertainties such as organ
movement,15 the literature identifies a number
of geometric uncertainties. Uncertainties are
associated with geometric distortion from the
MRI, but some studies have shown this can
be limited to 2 mm in the area of treatment.17
Another possible uncertainty is ‘reconstruction
of the applicator’; this is the process whereby
the geometry of the source channels and dwell
positions are defined on three dimensional
(3D) images to enable planning. Hack et al
describes a method of applicator reconstruction
for MRI18 via the visualisation of source
channels using catheters containing copper
sulphate.
Unlike when planning for EBR, electron
density information is not necessary for bra-
chytherapy planning; CT images are therefore
not needed.19 However, applicator reconstruc-
tion using CT images followed by CT-MR
fusion is still a widely reported method of
planning in the literature.20,21,22,23 It has been
shown that valuable information can be lost on
CT in between slices and this is less likely to
occur with MR reconstruction.20 Although
inter-observer variability due to image artefacts
is evident in applicator reconstruction with
MRI, the uncertainties in reconstruction can
be minimised as part of a stringent quality
assurance program,18 and particular care must
be taken when using conformal loading
patterns24.
PATIENT SPECIFIC PLANNING FOR
CERVICAL BRACHYTHERAPY:
WHAT IS THE EVIDENCE BASE?
The GEC-ESTRO recommendations for target
volume definition and dose reporting have been
adopted by the Royal College of Radiologists
Working Party,4 and are widely used in the lit-
erature to describe both planning studies and
clinical results.
Planning studies are often descriptive rather
than comparative, and are commonly used to
report the use of a new technique, giving a syn-
opsis of the dosimetric results. However, some
of these planning studies have compared new
techniques against old institutional prac-
tices.25,26 Planning studies also may be limited
as they have small sample sizes (between one
and twenty two patients in the surveyed studies)
and it is therefore debatable that the results are
transferable to the general patient population.
Nevertheless they do provide some useful
indications for future work, and importantly
identify some issues that can be followed up in
future studies. One study identified strategies
for treating large HR-CTV and OAR close to
the GTV with interstitial needles and/or adapt-
ing source dwell times.22 Another identified a
subgroup of patients that were problematic to
plan (severely antiflexed uterus), and subse-
quently developed two contrasting treatment
plans that either optimised target coverage or
improved organ sparing21.
Two papers were identified that directly
compared standardised loading/prescription to
point A against conformal loading using MRI
images.25,26 Although both studies found that
mean D90 (minimum dose delivered to 90%
of the volume) to the GTV increased slightly
when using MRI, mean rectal, bladder and
small bowel D1cc (dose to 1cc of most irra-
diated tissue) and 2 cc results were equivocal.
However, De Brabandere et al.25 emphasised
that the reporting of mean dose across a cohort
hides the specific advantages that conformal
loading brings to individual plans. For example,
when altering a standardised plan, the planner
would sometimes reduce a high D90 to the
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GTV in order to reduce dose to critical struc-
tures. Similarly, doses to critical structures
were sometimes increased (within tolerance) to
increase D90 coverage of the GTV.
Both studies used natural modifications of
existing techniques to allow MRI imaging and
non-conformal loading. MRI compatible ver-
sions of traditional applicators (the ring, and
tandem and ovoids, as used throughout UK
centres4 were used and the ‘pear shape’ dose
distribution was the common starting point for
planning (Figure 2). The plans produced by
three different types of applicator adapted for
MRI (tandem and ovoids, individual moulds
and Vienna ring) have been compared and
have shown relative equivalence, with differ-
ences in dose distribution quality attributed to
patient anatomy.27 Additional modifications of
traditional applicators have been developed,
such as the insertion of interstitial needles
through guide holes in the ring.22 Even when
dose distributions have been deliberately kept
close to the classic ‘pear shape’, interstitial
needles enabled larger GTVs to be treated to
higher doses without increasing OAR
doses.22,26
Clinical Results
Reporting of clinical results of MRI guided
planning for gynaecological brachytherapy are
often limited to case series reports. A series
from Vienna compares a cohort of consecutive
patients treated at a single institution before
and after a switch to MRI assisted planning.10
Data suggests that the use of MRI guidance
leads to both an overall reduction of toxicity
and an increase in local control and survival in
a subset of patients with tumours greater than
5 cm at implant.10 The authors reported that
interstitial needles allowed them to treat large
tumours, which they would have normally
treated with an EBR boost, but no comparison
of outcomes between these two options is
given. In Nayaran et al.28 a survival difference
was not observed after a switch from LDR
to MRI-planned HDR, but a significant
decrease in bowel and bladder symptoms is
reported.
What are the possible alternatives to MR
guided brachytherapy?
CT brachytherapy planning
In the UK, only one institution has reported on
the use of 3D imaging with cervix brachyther-
apy.29 This series from Addenbrooke’s NHS
Trust reported an increase in local control
and decrease in complications using CT plan-
ning when compared to standard loading and
prescribing to point A. The use of CT images
rather than MRI was necessary due to the
Figure 2. A cross-sectional view, through an intrauterine tube and vaginal ovoids, showing caesium pellet positions, and the resulting
dose distribution. The pear shape dose distribution is representative of a Manchester System treatment, which uses a standardised
pellet loading pattern.
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impracticality of scheduling MR scans to
coincide with intracavitary insertions at that
institution. In the UK in 2008, only 4% of
centres had access to brachytherapy planning
using MRI, and it is likely that many other
centres will see CT planning as an alternative.4
Data suggests that CT planning leads to larger
target volumes than MRI,23,29 and this series
reports a cautious use of dose optimisation as a
result, with V90 for patients limited by OAR
tolerance.
The Addenbrooke’s series utilised a ring
applicator, but does not use the additional
capability of the interstitial needles, and it
reported a lower increase in local control in
tumours greater than 5 cm compared to the
Vienna series. Addenbrooke’s relies more on
giving an EBR boost to patients with bulkier
tumours, and so the number of patients in their
series with tumours greater than 5 cm was
much lower than in the Vienna series.29 The
use of a conventional EBR boost when
brachytherapy is not possible is increasing at
other UK centres, and good survival and
complication rates can be seen using this
technique.30
What is the feasibility of the MRI-guided EBR
boost for cervix carcinoma?
A number of planning case studies have been
undertaken to understand the possible role of
an MR-guided IMRT boost in the treatment
of cervix carcinoma. Dosimetric comparison
between IMRT and brachytherapy is difficult
due to the dose inhomogeneity inherent in
brachytherapy, but there is evidence to suggest
that IMRT plans struggle to provide compar-
able V90 and V95 doses without compromising
normal tissue tolerances.31,32 One planning case
study reported that conventionally loaded or
optimised brachytherapy in combination with
a concomitant IMRT boost was superior to
optimised brachytherapy alone; this was parti-
cularly profound in cases where the uterus was
severely antiflexed.21
It must be noted that the above studies
assume that as the CTV is immobilised using
a stereotactic applicator, PTV margins are min-
imal. Implementation of IMRT after applicator
insertion would require quick turnaround of
planning and verification, which is logistically
challenging.21 Without stereotactic immobilisa-
tion, PTV margins surrounding the cervix and
uterus are greatly affected by internal organ
motion, and recent studies have tried to
quantify this problem in cervical cancer using
MRI.19,33 These studies in particular have
identified the influence of tumour regression
and OAR filling has on the position of the
GTV, and it is suggested that non-uniform
margins and interfractional imaging are
required if the aim is to achieve a reduction
in the PTV margin to reduce OAR toxicity.
IMPLEMENTING A CHANGE IN
TREATMENT DELIVERY FOR
CERVICAL CANCER
BRACHYTHERAPY
A change from LDR to PDR or HDR
machines requires a significant change in prac-
tice regardless of an institution’s decision to
use MRI, as new dose and fractionation regimes
would need to be determined to re-create the
radiobiological effects of LDR treatment using
the linear quadratic model.15,34 Although this
model has been used previously34 and is now
well accepted within the radiotherapy com-
munity,3 it must be emphasised that if a large
number of treatments are undertaken, any small
inaccuracies in the model are more likely to
have a detrimental clinical effect. So, although
MR optimisation may have mitigatory role,
clinical results must be closely monitored.
The introduction of MRI assisted planning
introduces an additional step into a treatment
process that is arguably simple and effective.
The maintenance of expertise in brachytherapy
has been recognised as a problem,35 and MRI
planning will add to the challenge of educating
and training practitioners as well as maintaining
those skills. To date there has been no specific
research that has explored staff training needs,
or evaluated the extra resources needed to plan
with MRI. In the literature, the time reported
to produce a plan ranged from 20 to 40 minutes
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per insertion,36 with around 1520 minutes
allocated for patient contouring.29 HDR treat-
ments may require multiple insertions, which
could result in extra time needed for contour-
ing. The use of interstitial needles would
require the use of supplementary theatre time
and the development of new skills; scheduling
MRI guidance would also require additional
co-ordination between infection control
experts, nurse, anaesthetists, diagnostic radio-
graphers and radiologists. CT planning would
also require additional staff training, quality
assurance procedures to be put in place and
the appropriate scheduling of CT planning
time. The limited availability of MRI to all bra-
chytherapy service providers in the UK may
require referral to neighbouring cancer centres
with MRI facilities and available capacity for
specific categories of patient.4
Although inverse planning solutions for
brachytherapy have been discussed in the
literature,2,5 the use of the ‘pear-shaped’ dose
distribution is still widely accepted as an import-
ant starting point for optimisation, and severe
deviations from it using inverse planning were
not apparent in the literature. Therefore, man-
ual optimisation may suffice, as no indication
is given in the literature that inverse planning
will reduce planning times. However, this could
be a future area of exploration that would
require the close collaboration between the
oncologist, the dosimetrist and the rest of the
planning and treatment delivery team, during
the early stages of implementation.
CONCLUSION
Brachytherapy is an important part of the treat-
ment of cervical cancer with radiotherapy, and
the use of MRI in planning and delivering
treatment allows the definition of macroscopic
and partially microscopic disease even after
initial EBR. HDR and PDR machines can
simulate the current techniques, but they also
facilitate the use of image guided brachytherapy
planning using MRI. Uncertainties in applicator
reconstruction and image fusion can be
minimised by developing appropriate quality
assurance systems, which address training and
resource issues.
Planning studies show the advantages of using
MRI to conform dose to the target volumes
identified by the GEC-ESTRO guidelines.
The majority of evidence favours the approach
of MR imaging with patient specific loading
compared to standardised loading and prescrib-
ing the use of the Manchester System. How-
ever, the reviewed clinical results for MRI
dose optimisation were limited and further clin-
ical trials will be needed to explore this further.
Although optimising plans using CT imaging
work on the same principles, the limited clinical
evidence so far does suggest that MRI is super-
ior for brachytherapy, especially in patients with
larger tumours. Currently those patients with
large tumours or patients that cannot have bra-
chytherapy frequently have a fractionated EBR
boost instead, which may be improved in the
future from the use of IMRT and MRI-CT
fusion for planning. Further studies into the def-
inition of organ movement and PTV reduction
may improve outcomes for this already well-
established and clinically acceptable technique.
Although the skill base in IMRT is already
well established, planning case studies in the
literature and current logistical difficulties with
dose verification would suggest that IMRT
boosts cannot be used as a direct alternative to
MR brachytherapy.
The process of dose optimisation throughout
the literature is still reliant upon the classic
‘pear-shape’ for a starting point. Dose con-
straints for volumes are as yet unproven in clin-
ical trials, so this could be an area for further
exploration. However, emphasis should still be
placed on ensuring that good clinical outcomes
are maintained.
Evidence suggests that there is no superiority
in using a particular type of applicator and it
would be therefore acceptable to continue
using the current styles of applicator if a switch
to MRI dose optimisation was to occur.
Although no formal assessment of skills and
time needed to implement a change to MR
brachytherapy has been published, the use of
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interstitial needles, particularly in conjunction
with MRI guidance, would require a new set
of skills across professions, as well as additional
time and new logistical solutions. Dedicated
staff across disciplines should be appointed to
co-ordinate learning during the introduction
of MRI planning, and education and training
should be offered along with the dissemination
of knowledge to the wider professional team.35
These staff, dependent on their scope of prac-
tice could be at consultant/advanced practice
level,35 and further role extension and develop-
ment of radiographers could be utilised more,
for example in vaginal vault insertions.35
References
1. Radstone D, Kunkler I. Cervix, body of uterus, ovary,
vagina, vulva, gestational trophoblastic tumours. In:
Bomford CK, Kunkler IH (eds), Walter and Miller’s
Textbook of Radiotherapy, Radiation Physics Therapy
And Oncology, 6th edn. London, Churchill Livingstone,
2003, pp. 456487.
2. Dewitt KD, Hsu IC, Speight J, Weinberg VK, Lessard E,
Pouliot J. 3D inverse treatment planning for the tandem
and ovoid applicator in cervical cancer. Int J Radiat Oncol
Biol Phys 2005; 63:12701274.
3. National Institute for Health and Clinical Excellence.
Interventional procedures overview of high dose rate bra-
chytherapy for carcinoma of the cervix. London, National
Institute for Clinical Excellence, 2005.
4. The Royal College of Radiologists. Implementing image-
guided brachytherapy for cervix cancer in the UK.
London, The Royal College of Radiologists, 2009.
5. Chajon E, Dumas I, Touleimat M, Magne´ N, Coulot J,
Verstraet R, Lefkopoulos D, Haie-Meder C. Inverse plan-
ning approach for 3-D MRI-based pulse-dose rate intra-
cavitary brachytherapy in cervix cancer. Int J Radiat
Oncol Biol Phys 2007; 69:955961.
6. Sankaranarayanan R, Ferlay J. Worldwide burden of gyn-
aecological cancer: the size of the problem. Best Pract Res
Clin Obstet Gynaecol 2006; 20:207225.
7. Patrick P, Michel R. Diagnosis and management of
cervical cancer. BMJ 2007; 345:765768.
8. Kehoe S. Treatments for gynaecological cancers. Best
Pract Res Clin Obstet Gynaecol 2006; 20:9851000.
9. Logsdon MD, Eifel PJ. Figo IIIB squamous cell carcinoma
of the cervix: an analysis of prognostic factors emphasizing
the balance between external beam and intracavitary radi-
ation therapy. Int J Radiat Oncol Biol Phys 1999;
43:763775.
10. Po¨tter R, Dimopoulos J, Georg P, Lang S, Waldha¨usl C,
Wachter-Gerstner N, Weitmann H, Reinthaller A,
Knocke TH, Wachter S, Kirisits C. Clinical impact of
MRI assisted dose volume adaptation and dose escalation
in brachytherapy of locally advanced cervix cancer.
Radiother Oncol 2007; 83:148155.
11. Viswanathan AN. The Frank Ellis memorial lecture: the
use of three-dimensional imaging in gynaecological
radiation therapy. Clin Oncol (R Coll Radiol) 2008;
20:15.
12. Khoo VS, Dearnaley DP, Finnigan DJ, Padhani A, Tanner
SF, Leach MO. Magnetic resonance imaging (MRI): con-
siderations and applications in radiotherapy treatment
planning. Radiother Oncol 1997; 42:115.
13. Barillot I, Reynaud-Bougnoux A. The use of MRI in
planning radiotherapy for gynaecological tumours. Cancer
Imaging 2006; 6:100106.
14. Dimopoulos JC, Schard G, Berger D, Lang S, Goldner G,
Helbich T, Po¨tter R. Systematic evaluation of MRI find-
ings in different stages of treatment of cervical cancer:
potential of MRI on delineation of target, pathoanatomic
structures, and organs at risk. Int J Radiat Oncol Biol Phys
2006; 64:13801388.
15. Haie-Meder C, Po¨tter R, Van Limbergen E, Briot E, De
Brabandere M, Dimopoulos J, Dumas I, Hellebust TP,
Kirisits C, Lang S, Muschitz S, Nevinson J, Nulens A,
Petrow P, Wachter-Gerstner N; Gynaecological (GYN)
GEC-ESTRO Working Group. Recommendations from
Gynaecological (GYN) GEC-ESTRO Working Group
(I): concepts and terms in 3D image based 3D treatment
planning in cervix cancer brachytherapy with emphasis
on MRI assessment of GTV and CTV. Radiother Oncol
2005; 74:235245.
16. Po¨tter R, Haie-Meder C, Van Limbergen E, Barillot I,
De Brabandere M, Dimopoulos J, Dumas I, Erickson B,
Lang S, Nulens A, Petrow P, Rownd J, Kirisits C;
GEC ESTRO Working Group. Recommendations from
gynaecological (GYN) GEC ESTRO working group
(II): concepts and terms in 3D image-based treatment
planning in cervix cancer brachytherapy-3D dose volume
parameters and aspects of 3D image-based anatomy, radi-
ation physics, radiobiology. Radiother Oncol 2006;
78:6777.
17. Anderson C, Beenstock V, Bryant L, Chapman C et al.
HDR brachytherapy of the cervix: The Mount Vernon
Experience. Brachytherapy User Group Meeting, Leeds;
2008.
18. Haack S, Nielsen SK, Lindegaard JC, Gelineck J,
Tanderup K. Applicator reconstruction in MRI 3D
image-based dose planning of brachytherapy for cervical
cancer. Radiother Oncol 2009; 91:187193.
19. Huh SJ, Park W, Han Y. Interfractional variation in posi-
tion of the uterus during radical radiotherapy for cervical
cancer. Radiother Oncol 2004; 71:7379.
20. Hellebust TP, Tanderup K, Bergstrand ES, Knutsen BH,
Røislien J, Olsen DR. Reconstruction of a ring applicator
using CT imaging: impact of the reconstruction method
207
Magnetic resonance imaging in cervical cancer
and applicator orientation. Phys Med Biol 2007;
52:48934904.
21. Duan J, Kim RY, Elassal S, Lin HY, Shen S. Conven-
tional high-dose-rate brachytherapy with concomitant
complementary IMRT boost: a novel approach for
improving cervical tumor dose coverage. Int J Radiat
Oncol Biol Phys 2008; 71:765771.
22. Kirisits C, Lang S, Dimopoulos J, Berger D, Georg D,
Po¨tter R. The Vienna applicator for combined intracavi-
tary and interstitial brachytherapy of cervical cancer:
design, application, treatment planning, and dosimetric
results. Int J Radiat Oncol Biol Phys 2006; 65:624630.
23. Viswanathan AN, Dimopoulos J, Kirisits C, Berger D,
Po¨tter R. Computed tomography versus magnetic reson-
ance imaging-based contouring in cervical cancer bra-
chytherapy: results of a prospective trial and preliminary
guidelines for standardized contours. Int J Radiat Oncol
Biol Phys 2007; 68:491498.
24. Berger D, Dimopoulos J, Georg P, Georg D, Po¨tter R,
Kirisits C. Uncertainties in assessment of the vaginal dose
for intracavitary brachytherapy of cervical cancer using a
tandem-ring applicator. Int J Radiat Oncol Biol Phys
2007; 67:14511459.
25. De Brabandere M, Mousa AG, Nulens A, Swinnen A,
Van Limbergen E. Potential of dose optimisation in
MRI-based PDR brachytherapy of cervix carcinoma.
Radiother Oncol 2008; 88:217226.
26. Lindegaard JC, Tanderup K, Nielsen SK, Haack S,
Gelineck J. MRI-guided 3D optimization significantly
improves DVH parameters of pulsed-dose-rate bra-
chytherapy in locally advanced cervical cancer. Int J
Radiat Oncol Biol Phys 2008; 71:756764.
27. Langa S, Nulensb A, Briotc E et al. Intercomparison of
treatment concepts for MR image assisted brachytherapy
of cervical carcinoma based on GYN GEC-ESTRO
recommendations. Radiother Oncol 2006; 78:185193.
28. Narayan K, van Dyk S, Bernshaw D, Rajasooriyar C,
Kondalsamy-Chennakesavan S. Comparative study of
LDR (Manchester system) and HDR image-guided con-
formal brachytherapy of cervical cancer: patterns of failure,
late complications, and survival. Int J Radiat Oncol Biol
Phys 2009; 74:15291535.
29. Tan LT, Coles CE, Hart C, Tait E. Clinical impact of
computed tomography-based image-guided brachyther-
apy for cervix cancer using the tandem-ring applicator 
the Addenbrooke’s experience. Clin Oncol (R Coll
Radiol) 2009; 21:175182.
30. Barraclough LH, Swindell R, Livsey JE, Hunter RD,
Davidson SE. External beam boost for cancer of the cervix
uteri when intracavitary therapy cannot be performed. Int
J Radiat Oncol Biol Phys 2008; 71:772778.
31. Georg D, Kirisits C, Hillbrand M, Dimopoulos J, Po¨tter
R. Image-guided radiotherapy for cervix cancer: high-
tech external beam therapy versus high-tech brachyther-
apy. Int J Radiat Oncol Biol Phys 2008; 71:12721278.
32. Assenholt MS, Petersen JB, Nielsen SK, Lindegaard JC,
Tanderup K. A dose planning study on applicator guided
stereotactic IMRT boost in combination with 3D MRI
based brachytherapy in locally advanced cervical cancer.
Acta Oncol 2008; 47:13371343.
33. van de Bunt L, Jurgenliemk-Schulz IM, de Kort GAP,
Roesink JM, Terteeg RJHA, van der Heide UA. Motion
and deformation for cervical cancer: what margins do we
need? Radiother Oncol 2008; 88:234240.
34. Petereit DG, Sarkaria JN, Potter DM, Schink JC. High-
dose-rate versus low-dose-rate brachytherapy in the treat-
ment of cervical cancer: analysis of tumor recurrencethe
University of Wisconsin experience. Int J Radiat Oncol
Biol Phys 1999; 45:12671274.
35. The Royal College of Radiologists. The Role and Devel-
opment of Brachytherapy Services in the United Kingdom.
London: The Royal College of Radiologists, 2007.
36. Dimopoulos JCA, Kirisits C, Petric P et al. The Vienna
Applicator and interstitial brachytherapy of cervical
cancer: clinical feasibility and preliminary results. Int J
Radiat Oncol Biol Phys 2006; 64:5.
208
Magnetic resonance imaging in cervical cancer
